Savara to present Phase 3 IMPALA-2 molgramostim data in autoimmune pulmonary alveolar proteinosis at ERS 2026

• Savara flagged new Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis at the ERS Congress, Sept. 5-9, 2026.
• Results will be presented in the future, including an oral session on Sept. 6 covering longer-term efficacy and safety from the open-label period.
• Data indicate sustained gains in lung function, exercise capacity, and quality of life, supporting molgramostim as a potential long-term treatment option.
• Separate analyses point to reductions in disease-related biomarkers, suggesting the therapy may address underlying disease biology.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202608241605BIZWIRE_USPR_____20260824_BW428528) on August 24, 2026, and is solely responsible for the information contained therein.